Published in J Clin Transl Hepatol on December 15, 2013
CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med (2006) 22.76
Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90
The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med (2006) 18.63
Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep (2012) 6.91
Viral hepatitis in HIV infection. N Engl J Med (2007) 4.18
Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol (2011) 3.67
Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis (2013) 3.17
Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science (1987) 2.51
Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study. Clin Infect Dis (2005) 2.35
Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med (2013) 2.25
Hepatitis C virus infection among adolescents and young adults:Massachusetts, 2002-2009. MMWR Morb Mortal Wkly Rep (2011) 2.18
Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir. Clin Infect Dis (2012) 1.91
Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA (2012) 1.88
Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr (2006) 1.87
Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology (2009) 1.64
Primary liver cancer is more aggressive in HIV-HCV coinfection than in HCV infection. A prospective study (ANRS CO13 Hepavih and CO12 Cirvir). Clin Res Hepatol Gastroenterol (2011) 1.62
Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection. Am J Gastroenterol (2010) 1.56
Acute hepatitis C in HIV-infected men who have sex with men. HIV Med (2004) 1.26
The association of hepatitis C prevalence, activity, and genotype with HIV infection in a cohort of New York City drug users. J Acquir Immune Defic Syndr (2003) 1.19
Current management of hepatitis C virus infection in patients with HIV co-infection. J Infect Dis (2013) 1.15
Pathogenesis of accelerated fibrosis in HIV/HCV co-infection. J Infect Dis (2013) 1.14
Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir. Antivir Ther (2013) 1.12
Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Hepatitis-HIV Spanish Study Group. Clin Infect Dis (1996) 1.04
Hepatitis C coinfection is independently associated with decreased adherence to antiretroviral therapy in a population-based HIV cohort. AIDS (2006) 1.00
Update on HIV/HCV coinfection. Curr HIV/AIDS Rep (2013) 1.00
Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis (2005) 0.99
Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy. J Acquir Immune Defic Syndr (2005) 0.98
Pharmacokinetic interaction between boceprevir and etravirine in HIV/HCV seronegative volunteers. J Acquir Immune Defic Syndr (2013) 0.93
Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients. Antivir Ther (2007) 0.92
Lack of a clinically significant drug-drug interaction in healthy volunteers between the hepatitis C virus protease inhibitor boceprevir and the HIV integrase inhibitor raltegravir. Clin Infect Dis (2012) 0.92
The natural history of early hepatitis C virus evolution; lessons from a global outbreak in human immunodeficiency virus-1-infected individuals. J Gen Virol (2011) 0.92
New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals. J Antimicrob Chemother (2010) 0.91
Virological response rates for telaprevir-based hepatitis C triple therapy in patients with and without HIV coinfection. HIV Med (2013) 0.89
Review of drug interactions with telaprevir and antiretrovirals. Antivir Ther (2013) 0.88
Risk of liver decompensation among HIV/hepatitis C virus-coinfected individuals with advanced fibrosis: implications for the timing of therapy. Clin Infect Dis (2013) 0.87
Depressive symptoms after initiation of interferon therapy in human immunodeficiency virus-infected patients with chronic hepatitis C. Antivir Ther (2004) 0.83
CROI 2013: Complications of HIV disease, viral hepatitis, and antiretroviral therapy. Top Antivir Med (2013) 0.78